Antibiotics exposure linked to increased colon cancer risk
In an extensive data mining analysis of British medical records, researchers at the Johns Hopkins Kimmel Cancer Center have concluded that taking even a single course of antibiotics might boost--albeit slightly--the risk of developing colon cancer--but not rectal cancer--a decade later.
The findings, reported in the journal Gut , highlight the need for judicious use of this broad category of drugs, which are frequently improperly or overprescribed.
The primary message of this study is the importance of antibiotic stewardship: not treating common viral infections with antibiotics, using them for the shortest time period possible, and using targeted antibiotics rather than broad spectrum ones.
This research has indicated that these drugs can have significant off-target effects, including the induction of chronic illnesses.
Antibiotics are widely prescribed throughout the world to treat bacterial infections, and there is growing evidence, including several epidemiological database studies, that link use of these drugs to the risk of colorectal cancer.
However, the past studies have had a variety of drawbacks, including failure to control for other colorectal cancer risk factors ( family history, history of obesity, smoking, alcohol use, and diabetes ) recall bias in patients' recollections about antibiotic use, failure to separate data about colon and rectal cancers, and too few study participants to produce meaningful conclusions.
To learn more about the association between antibiotics and colorectal cancers, researchers mined data from the Clinical Practice Research Datalink ( CPRD ), one of the world's largest electronic medical record databases of anonymized clinical records, information that does not identify individual patients.
CPRD holds information on more than 11 million patients in the U.K., including data on drug prescribing and diagnoses, making this study the first population-based study to examine the association of antibiotic exposure and risk of colorectal cancer.
Focusing on a 23-year period from January 1, 1989, to December 31, 2012, the researchers found 28,890 cases of colorectal cancer.
They matched each of these patient records with up to five healthy controls who never developed this disease, but who had similar characteristics, including age, gender, and where their general practitioner practiced, for a total of 137,077 control cases for comparison.
They then used the medical records to identify and evaluate each case history for colorectal cancer risk factors, such as a history of obesity, smoking, alcohol use, and diabetes, as well as antibiotic use.
As expected, the researchers found that those patients who developed colorectal cancer were more likely to have one or more of the known risk factors.
However, when they accounted for these factors in their statistical evaluation, they found that those who developed colon cancer were slightly more likely to have been exposed to antibiotics ( 71.3% compared to 69.1% ).
Those with rectal cancers did not show that association and had about the same antibiotic exposure compared to healthy subjects.
Further investigation showed that antibiotic exposure was only associated with increased risk of approximately 15% for cancer in the proximal colon but not the distal colon, and this risk happened particularly after exposure to classes of antibiotics that kill anaerobic bacteria, such as those in the Penicillin family.
Among the compelling findings, was the rapid onset of increased colon cancer risk, beginning with only 15-30 days of total antibiotic exposure ( approximately 8% increased risk with 15-30 days of total antibiotic exposure and approximately 15% increased risk with 30 or more days of total antibiotic exposure ).
However, the association was reversed for rectal cancer: the more total antibiotic exposure, specifically total exposures of 60 days or more, the less likely they were to have cancer in this location.
Cancers that developed in the colon were linked with antibiotic exposure at least 10 years earlier. There was no increased risk with exposures less than 10 years prior.
Although antibiotics are most often highly effective at eradicating bacterial infections, they also can change the balance of the gut biome by killing beneficial bacteria and allowing pathogenic ones to thrive.
Some of these surviving bacteria could be carcinogenic, encouraging polyps to grow and develop into malignant tumors.
In recent years, probiotic-rich foods and supplements have become popular, in part to address gut biome imbalances. But the data on probiotics is mixed with some studies showing positive effects and others showing no effects or negative effects of using these supplements.
Rather than trying to add beneficial bacteria back to the intestines, a better way to avoid potentially increased colon cancer risk from antibiotic use is through more cautious prescribing of antibiotics. ( Xagena )
Source: Johns Hopkins Kimmel Cancer Center, 2019
Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within...
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...
European Commission has approved Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...
Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...
Advanced renal cell carcinoma: outcomes based on age in the phase III METEOR trial of Cabozantinib versus Everolimus
Cabozantinib ( Cabometyx ) has improved progression-free survival ( PFS ), overall survival ( OS ) and objective response rate...
FDA: Opdivo plus Yervoy as first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression greater than or equal to 1%
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...
Metastatic non-small cell lung cancer: Tecentriq has demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy - FDA has approved
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) as a first-line treatment for...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...